02/18/2026
Congratulations to Rupan Trikha, M.D., and the team at Monmouth Retina on performing the first Encelto®️ implant in New Jersey, bringing an FDA-approved treatment option to patients living with Macular Telangiectasia Type 2.
Encelto offers something patients have never had before: a therapy designed to slow progression and help preserve remaining vision, rather than only managing secondary complications.
If you’ve been diagnosed with MacTel Type 2, talk with your eye care provider about whether this new treatment option may be right for you.